1. High FRMD3 expression is prognostic for worse survival in rectal cancer patients treated with CCRT
- Author
-
Wan-Shan Li, Hong-Lin He, Hsin-Hwa Tsai, Tzu-Ju Chen, Hong-Yue Lai, Cheng-Fa Yeh, Yu-Feng Tian, Ti-Chun Chan, Chien-Feng Li, and Chia-Lin Chou
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Multivariate analysis ,Colorectal cancer ,business.industry ,Cytoskeletal protein binding ,Hematology ,General Medicine ,Lymph node metastasis ,medicine.disease ,03 medical and health sciences ,Tumor Status ,030104 developmental biology ,0302 clinical medicine ,Surgical oncology ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Immunohistochemistry ,Surgery ,business ,Chemoradiotherapy - Abstract
Rectal cancer patients can conceivably obtain relief from neoadjuvant concurrent chemoradiotherapy (CCRT) for downstaging before resection, but the stratification of risk and clinical outcomes remains challenging. Therefore, identifying effective predictive biomarkers offers clinicians the opportunity to individually tailor early interventions, which would help optimize therapy. Using a public rectal cancer transcriptome dataset (GSE35452), we focused on cytoskeletal protein binding (GO: 0008092)-related genes and identified FERM domain containing 3 (FRMD3) as the most significant differentially expressed gene associated with CCRT resistance. We gathered 172 tumor samples from rectal cancer patients treated with neoadjuvant CCRT accompanied by curative resection and estimated the expression level of FRMD3 using immunohistochemistry. The results revealed that high FRMD3 immunoexpression was remarkably associated with advanced pre-CCRT and post-CCRT tumor status (p = 0.004 and p
- Published
- 2021